Threshold Pharmaceuticals, Inc (THLD): Opiniones

Pues es verdad, doblando la media. No me había fijado en esto. Al parecer la noticia ha sido bien acogida por el mercado.
A ver si esta nos arregla un poco el veranito.

te comente que el semanal cantaba hace unas semanas, seguro no hay nada, lo que tenemos es la expectativa de septiembre, el pipeline que no deja de crecer y merck haciendo de proxeneta, no olvidar a los panadero que no se salen y están callados como una puta, sería interesante saber si han aumentado posición, aunque llevan su parte en el pastel, de brean paso tanto como de zacks o piper jaffray.
El cocinero pues esta dentro parece que no se sale ni con en el amago caída de hoy.

Dará entrada durante julio y agosto seguro.

Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") in Final Stage of Ongoing Phase 1/2 Trial of Patients With Relapsed/Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/09/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib (Velcade®) and low-dose dexamethasone ("TBorD") in patients with relapsed/refractory multiple myeloma, a cancer of the bone marrow.

Initial results from the dose-escalation and dose-expansion stages of the trial evaluating TH-302 and low-dose dexamethasone without bortezomib were recently presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). As reported at ASCO, patients were heavily-pretreated (median 6.5 prior systemic therapies), and objective responses were observed in 5/16 (31%) patients (three partial responses and two minimal responses) treated at the maximum-tolerated dose of TH-302 (340 mg/m2).1

"Data seen thus far are encouraging using the combination of TH-302 and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma," said Irene Ghobrial, M.D., Medical Oncologist at Dana-Farber/Brigham and Women's Cancer Center and Principal Investigator of the Phase 1/2 trial. "I would like to acknowledge the Blood Cancer Research Partnership for their significant role in facilitating rapid accrual of patients to this study. We are excited to initiate this final stage in which patients will receive TH-302, bortezomib, and dexamethasone, particularly in light of preclinical research demonstrating synergistic cytotoxicity of TH-302 and bortezomib."

In the U.S. and Europe, there are an estimated 66,000 new cases of multiple myeloma per annum.2,3 Current standards of care include alkylating agents, proteasome inhibitors, and immunomodulatory drugs (IMiDs). New treatment options for patients with advanced multiple myeloma who experience relapse of their disease or who become refractory to standard therapies remains an area of unmet medical need.

"The presence of hypoxia in the diseased bone marrow may present a new therapeutic target for treating multiple myeloma and underscores my enthusiasm for further evaluation of TH-302 in this disease," said Jacob Laubach, M.D., Clinical Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber/Brigham and Women's Cancer Center and a lead investigator on the Phase 1/2 trial.

The bone marrow in patients with multiple myeloma has been shown to be hypoxic,4,5 and hypoxia has been implicated in the progression of multiple myeloma in vitro and in vivo.6 TH-302 is a hypoxia-activated prodrug that is designed to selectively release bromo-isophosphoramide mustard (Br-IPM), a potent DNA-alkylating agent, under conditions of tumor hypoxia. TH-302 has demonstrated antimyeloma activity both in vitro and in vivo as well as synergistic cytotoxic activity with bortezomib in vitro.7-9

Menos mal que esa media era irrelevante, nos tapona más que Gasol. Si la rompemos volamos, mientras enrangados entre ella y los 4.00.

Articulistas, analistas, bloggers ...

https://www.tipranks.com/stocks/thld

Cada uno con un link a su articulo

Brean Capital reitera su BUY y PO a 15$
http://www.watchlistnews.com/threshold-pharmaceuticals-receives-new-coverage-from-analysts-at-brean-capital-thld/55731/

Up up up ¡¡¡

esperando la rotura por enésima vez.